Claritev Corporation Earnings Recaps
Q2 2026
Aug 9, 2026
Claritev's stock surged 21.4% following an earnings report that beat expectations on key metrics including bookings and revenue, driven by strong momentum in the third-party administrator (TPA) segment and expanding opportunities in Medicare Advantage.
Key takeaways
- Bookings exceeded $74 million in the first half of 2026, well on track for the $100 million full year stretch target.
- The TPA segment led new bookings with multiple 7-figure deals, accounting for roughly 30% of total new bookings and showing immediate progress under new leadership.
- Revenue and adjusted EBITDA both came in above plan, validating the company’s transformation strategy and operational execution.
- Growth is supported by increasing deal sizes, improved win rates, and a healthy sales pipeline across core and emerging verticals.
- Emerging Medicare Advantage opportunities reflect the company’s successful diversification strategy, expanding its addressable market beyond traditional segments.
Q3 2025
Nov 8, 2025
Claritev Corporation reported a strong Q3 2025, delivering higher-than-expected revenue and adjusted EBITDA growth, reaffirming the successful execution of its strategic turnaround ahead of schedule.
Key takeaways
- Revenue increased by 6.7% and adjusted EBITDA grew by 9.5%, both surpassing internal projections.
- The company renewed contracts with its top 10 clients, providing stability and a solid foundation for growth.
- Added 5 new logos and closed $15 million in Annual Contract Value, with a 25% increase in average ACV per transaction.
- Significant growth across all six focused market verticals, indicating effective alignment and execution of strategic priorities.
- Pipeline growth reflected a 67% increase year-to-date, showcasing a robust expansion strategy in new client acquisition and existing client value enhancement.